Targeted treatment for specific tumors using 177Lu-TATE-RGD
Therapeutic Efficiency and Response to 177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
This study is testing a new drug called 177Lu-TATE-RGD to see if it can help patients with certain tough-to-treat tumors that haven't responded to other treatments.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06632873 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of 177Lu-TATE-RGD, a novel drug targeting integrin αVβ3 positive tumors, in patients who have not responded to conventional treatments. Participants will undergo PET/CT screening to confirm the presence of specific tumor markers before receiving an intravenous injection of the drug. Blood samples will be collected at various intervals post-injection to measure radioactivity, and imaging will be conducted to assess the therapeutic effects and response over time.
Who should consider this trial
Good fit: Ideal candidates are patients with confirmed SSTR2 and RGD positive tumors who have not responded to standard treatments.
Not a fit: Patients with severe renal impairment, low blood counts, or other significant medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new targeted therapy option for patients with difficult-to-treat tumors.
How similar studies have performed: While this approach is novel, previous studies have shown promise in using targeted therapies for similar tumor types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with clear pathological diagnosis and ineffective or progressing clinical conventional treatment; * tumor lesions with high SSTR2 and RGD untake confirmed on 68Ga-TATE-RGD PET/CT within one week before the injection of 177Lu-TATE-RGD; * signed written consent. Exclusion Criteria: * the exclusion criteria were a serum creatinine level of more than 150 μmol per liter, a hemoglobin level of less than 10.0 g/dl, a white-cell count of less than 4.0× 109/L, a platelet count of less than 100 × 109/L, a total bilirubin level of more than 3 times the upper limit of the normal range and a serum albumin level of more than 3.0 g per deciliter, cardiac insufficiency including carcinoid heart valve disease, a severe allergy or hypersensitivity to radiographic contrast material, claustrophobia; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Where this trial is running
Beijing, Beijing Municipality
- Chinese Academy of Medical Science & Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Zhaohui Zhu, MD
- Email: 13611093752@163.com
- Phone: 13611093752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.